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ABSTRACT
Objective: To study the drug utilization pattern in patients suffering from primary open-angle glaucoma (POAG) in a tertiary care teaching hospital.
Methods: It is a prospective study done on 50 patients of POAG (comprising of individuals belonging to any age group). This study was carried for a 
period of 2-month, and the data included patient’s demographic details and the drugs prescribed. Data were analyzed for drug use pattern.
Results: After screening the prescriptions of patients, it was found out that out of total 50 prescriptions, 30 were males, and 20 were females. Out of 
50 prescriptions, prostaglandins (58%) were most commonly prescribed. β-blockers (16%) were also prescribed. Fixed dose combination constituted 
60% of the prescriptions. Instructions about the route, frequency, and duration of treatment were present in all prescriptions. Drugs prescribed by 
their generic names were 18.75% and about 81.25% of the drugs were prescribed by their brand names.
Conclusions: Fixed drug combination of timolol and dorzolamide was the most frequently prescribed combination. Prescribers must be aware of 
importance of prescribing drugs with generic names.
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INTRODUCTION
Glaucoma is a condition that involves distinctive changes in the optic 
nerve and visual field [1]. It is marked by raised intraocular pressure 
(IOP) that compresses and damages the optic nerve. Once the optic 
nerve is damaged, it fails to carry the visual information to the brain 
and these results in a clinically progressive loss of peripheral visual 
field and ultimately vision. Primary open-angle glaucoma (POAG) is 
defined as chronic optic neuropathy with characteristic changes in 
the optic disc and visual field. This optic nerve damage can ordinarily 
be alleviated and inhibited by sufficiently reducing IOP by various 
antiglaucoma medications [2,3].
Risk factors for POAG include older age, black race, family history 
(first-degree relative), thinner central corneal thickness, myopia, 
diabetes mellitus, high blood pressure, thyrotoxicosis, corticosteroid 
responsiveness, and elevated IOP [4,5].
Prevalence of POAG varies in different populations. Glaucoma is 
estimated to affect about 6.48 million [6]. In general, it affects about 1 
in 100 of the general population (of either sex) above the age group of 
40 years. It forms about one-third cases of all glaucomas [4]. In India, 
there are approximately 11.2 million persons aged 40 years and older 
suffering with glaucoma [7].
All the drugs prescribed for glaucoma will be recorded including its 
dosage form, route of administration, frequency of administration, 
indications for which prescribed and duration of therapy. The aim of 
treatment of POAG is to lower IOP to a level where (further) visual 
loss does not occur. The IOP needs to be maintained at a lower level of 
11-20.5 mm Hg [8]. Drugs used for POAG may be single drug therapy or 
combination topical therapy. Role of oral carbonic anhydrase inhibitors, 
hyperosmotic agents, and neuroprotective agents are also undertaken. 
Single drug therapy includes topical β-blockers (decreases aqueous 
secretion), prostaglandin analogs (increases the uveoscleral outflow), 
adrenergic drugs (increases aqueous outflow/decreases aqueous 
production and increases uveoscleral outflow), carbonic anhydrase 
inhibitors (decreases aqueous production), and pilocarpine (opens 
trabecular meshwork and increases aqueous outflow). In combination 
topical therapy, if one drug is not effective, then combination of two 
drugs, one drug which decreases aqueous production and other drug 
which increases aqueous outflow may be used [4]. The drug utilization 
90% (DU 90%) index was introduced as a simple, inexpensive, and 
flexible method for assessing the quality of the drug prescriptions. It 
identifies the drugs accounting for 90% of the volume of the prescribed 
drugs after ranking the drug used by volume of defined daily dose [9]. 
Third world countries spend 30-40% of their total health budget 
on drugs, some of which are useless and expensive and double their 
expenditure on drugs on every 4 years while GNP (gross national 
product) doubles every 16 years [10].
Periodical auditing of DU pattern is vital for promotion of rational 
use of drugs. The newer glaucoma medications have advantages such 
as increased efficacy, reduced dosing frequency, and improved side 
effect profile. Studies related to DU in glaucoma reported from India 
are scarce [11]. Hence, this study was undertaken to determine the 
prescribing pattern of antiglaucoma drugs in Outpatient Department 
(OPD) of a tertiary care teaching hospital.
METHODS
It is a prospective study done on 50 patients with POAG (comprising 
of individuals belonging to any age group), enrolled in the OPD 
of Ophthalmology (glaucoma clinic), Bhaskar General Hospital. 
Institutional Ethics Committee clearance was obtained before starting 
the study, and informed consent form was obtained from the patient 
during the study. This study was carried for a period of 2-month, 
i.e. 8 weeks, and data were recorded.
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The importance and need for the study will be explained to each 
patient. After obtaining the informed consent, the data will be collected 
from patients, who were diagnosed with POAG by the ophthalmologist. 
Prescriptions of patients treated for glaucoma during the study will 
be audited, and they are collected from OPD. All the drugs prescribed 
for glaucoma will be recorded including its dosage form, route of 
administration, frequency of administration, indications for which 
prescribed and duration of therapy. These prescriptions will then be 
analyzed to check the average number of drugs per prescription, number 
of encounters with antibiotics, anti-inflammatory drugs and other 
agents, dosage form of drugs, the frequency of drug administration and 
the duration of therapy (mentioned or not) and whether the drugs will 




Number of patients enrolled in the study are 50 suffering with POAG 
attending the OPD of Ophthalmology, Bhaskar General Hospital over a 
period of 2 months.
Study design
The following data will be collected from the prescriptions of patients 
suffering with POAG and are recorded in the study. Patient particulars, 
history, diagnosis, drugs - the dosage, frequency, and duration of 
treatment, comorbid conditions, generic or brand prescription 




• Patients of any age group
• Patients of either gender
• Patients treated in the ophthalmology department for glaucoma.
B. Exclusion criteria
• Patients who will be diagnosed with other ophthalmological 
conditions.
Statistical analysis
Data collected were analyzed by Chi-square test. Statistical analysis 
showed positive correlation with *p<0.05.
RESULTS
After screening prescription of patients, it was found out that out of 
total 50 prescriptions, 30 were males, and 20 were females. In the 
50 analyzed prescriptions, 16 drugs were prescribed. Analysis of the 
prescriptions showed that the average number of drugs per prescription 
was 2.02 (Table 1). Regarding the dosage forms (Fig. 1), it was found 
that the maximum number of drugs prescribed were in the form of 
eye drops (93.3%), followed by tablets (6.67%), whereas capsules, 
ointments, syrups, and injections were accounting to 0% (Table 2). The 
antibiotics, anti-inflammatory, and antiallergic drugs, mydriatics and 
cycloplegics, miotics, multi-vitamins, lubricant, and miscellaneous eye 
drops prescribed were “nil.” The dosage form indicated was 100%. The 
frequency of drug administration indicated to all the drugs is 100%. 
Similarly, the drugs prescribed by their generic names were 18.75% 
and about 81.25% of the drugs were prescribed by their brand names 
(Table 3).
DISCUSSION
After screening of 50 POAG patients prescriptions, it was found that 
there was no sex preponderance (M:F=3:2). Among the patients and the 
maximum number of patients belong to the age group of 50-65 years. 
These findings showed that glaucoma is usually not sex-linked but 
may be age related. The study was also a part of the prescription audit. 
Patients with POAG were treated by various drugs in different dosage 
forms, and ongoing medical treatment was modified according to 
chemical response and most common drugs prescribed were β-blockers, 
carbonic anhydrase inhibitors, prostaglandin analogs, α-adrenergic 
drugs. The highest used drugs are carbonic anhydrase inhibitors. It 
has been recommended that the limited number of drugs prescribed 
per prescription should be “two” and that justification for prescribing 
more than two drugs would be required because of increased risk of 
drug interactions [12]. In this study, the average number of drugs per 
prescription was 2.02. Therefore, it is advisable to keep the number 
of drug prescriptions as low as possible since higher figures lead to 
Table 1: Number of drugs prescribed per prescription







Table 2: Major therapeutic agents and dosage forms of 
antiglaucoma drugs
Dosage form Major therapeutic agent
Drops 14 (93.33%) Timolol (Iotim)
Betaxolol (Iobet)







Oral 1 (6.67%) Acetazolamide (tablet diamox)
Table 3: Analysis of prescriptions of patients with respect to 
different parameters
S. No. Drug use indicators Results
1 Total number of prescriptions 50
2 Average number of drugs per prescription 2.02
3 Percentage of dosage forms recorded 100%
4 Percentage of frequency of therapy recorded 100%
5 Percentage of duration of therapy recorded -
6 Percentage of drugs prescribed by generic name 18.75%
7 Percentage of drugs prescribed by brand name 81.25%
Fig. 1: Formulation of medication
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increased risk of drug interactions, increased hospital cost of errors 
of prescribing [12-14]. The frequency, dosage, and duration of drug 
therapy are the three important parameters, if not clearly recorded, can 
result in indiscriminate and injudicious use of drugs. The present study 
showed that the dosage and frequency recorded in the prescriptions 
was 100%, but the duration of therapy was not recorded in any. When 
the various dosage forms were compared, it was found that eye drops 
were commonly prescribed followed by tablets. The results were 
similar to other studies, in which the maximum number of drugs 
prescribed was in the form of eye drops, followed by tablets [15]. This 
finding supports the use of topical preparations for treating POAG as 
they have site-specific action, less systemic absorption resulting in 
fewer side effects and convenient for the patient use. Percentage of 
drugs prescribed in POAG by their generic names in our study were 
18.25%, which is almost similar to one study (19%) as well as contrast 
(53.6%) to some other studies [16,17] while the brand names were 
81.75%. It suggests the popularity of brand names among the medical 
practitioners of the institute and the influence of pharmaceutical 
companies. Prescriptions by brand names could possibly result in 
prescribing errors because the brand names of many pharmacologically 
different drugs may sound alike and spell similar. As a matter of fact, 
generic drugs are less expensive as compared to brands that contain 
the same active ingredient. So, the prescriptions of generic drugs 
should be emphasized to facilitate cheaper and better treatment for 
the patient. Our study is in accordance with the WHO recommendation 
that average number of drugs per prescription should be “two.” There 
was no evidence of polypharmacy. The common prescription writing 
errors were minimum. Hence, our study on analysis of prescriptions 
of POAG patients showed a remarkable restraint on prescribing, no 
polypharmacy and no irrational drug combinations. Statistical analysis 
showed a positive correlation with p<0.05. However, there is a need 
for awareness to use more generic prescriptions as it could facilitate 
cheaper treatment for patients. Further studies are needed to delineate 
treatment of glaucoma [18].
CONCLUSION
Fixed drug combination of timolol (β-blocker) and dorzolamide 
(carbonic anhydrase inhibitors) was most frequently prescribed 
combination.
The percentage use of brand drugs is very high; hence, it is necessary 
to make prescribers aware of the importance of prescribing drugs with 
generic names.
Polypharmacy is not seen, and prescription errors were minimum in our 
study which concludes with overall impression of rational prescription.
Thus, periodical auditing of the prescriptions will help to measure the 
impact of the intervention on the prescribing pattern and improve 
rational pharmacotherapeutics.
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